Jan. 24 BREMERTON Harrison Medical Center ranks among the best hospitals in the nation at preventing injuries to patients. That's according to a report released last month by the Centers for Medicaid and Medicare Services, which scored hospitals on their ability to keep patients safe while under their care. Kaiser Health News reported more than
Jan. 24 CHAMBERSBURG Thousands of local Medical Assistance patients will have to switch health plans or find a new doctor. Aetna Better Health is ending its agreement with Chambersburg- based Keystone Health Center. We are really in between a rock and a hard place, "said Karen Shubert of Fayetteville, whose 5- year-old daughter is a patient at
Swedish biotech company Aprea has secured orphan drug designation from the European Medicines Agency for its anti-cancer agent APR-246 to treat ovarian cancer. Currently, the company is conducting a Phase Ib/II trial of APR-246 in combination with carboplatin and pegylated doxorubicin, a second line standard of care chemotherapy in patients with...
While the group gave an F to Kern Medical Center, it gave Cs to Bakersfield Heart Hospital, Bakersfield Memorial Hospital and San Joaquin Community Hospital. Dignity Health's Mercy Hospital campuses downtown and in the southwest each got Bs. Mercy Hospital downtown and the southwest campus tied for the lowest local scores for serious breathing prob
Proposed legislation that would legalize marijuana use for medical purposes the Cannabis Compassion and Care Act isn't going to gain any traction in the Statehouse this year. Informational hearings conducted by the Senate Public Health and Welfare Committee on Wednesday and Thursday first for advocates then for opponents are likely to be th
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration has approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
The US Food and Drug Administration has cleared Advaxis' investigational new drug application to conduct a Phase I clinical trial of ADXS-HER2 to treat patients with metastatic HER2 expressing solid tumors. In May 2014, the company secured orphan drug designation from the FDA for ADXS-HER2 in osteosarcoma. Advaxis president and chief executive offi
Harris Williams& Co. reported an investment in TrialCard, a provider of patient access and adherence services to the pharmaceutical and biopharmaceutical industry, from Excellere Partners. According to a company release, the transaction was led by Derek Lewis, James Clark, Paul Hepper and Taylor Morris of Harris Williams& Co.' s Richmond office and
Shire plc notes the announcement today by NPS Pharmaceuticals, Inc. that the U.S. Food and Drug Administration has approved NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH.
Marathon Pharmaceuticals said the U.S. Food and Drug Administration has granted Fast Track designation for deflazacort in the treatment of patients with Duchenne Muscular Dystrophy. A NDA is anticipated in early 2016. FDA previously granted Orphan Drug designation to deflazacort for the treatment of DMD. Marathon chief executive officer, Jeffrey Ar
DUBAI, 24th January, 2015 Dr. Amin Hussein Al Amiri, Assistant Under-Secretary of the Ministry of Health for the public health sector and licensing policy, has announced the fifth initiative of the Ministry of Health to reduce the prices of innovative medicines, and ease burden on patients. Al Amiri commended all the efforts of international phar
Traditional therapies use low-frequency spinal cord stimulation, but Nevro has developed Senza to deliver up to 10,000 Hz of high-frequency stimulation. The letter stated that Senza is approvable by the strength of the clinical data, but still will need to meet compliance with the FDA's Quality System Regulation, which evaluates the manufacturing..
ProHEALTH Care Associates and UnitedHealthcare said they are collaborating to improve care coordination and provide enhanced health services to more than 35,000 local residents enrolled in UnitedHealthcare's employer-sponsored health plans, including Oxford Health- branded plans. More than 600 providers practicing across ProHEALTH's 180...
Shire plc notes the announcement today by NPS Pharmaceuticals, Inc. that the U.S. Food and Drug Administration has approved NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Shire's Chief Executive Officer, Flemming Ornskov, MD, MPH, commented:. "The FDA's approval of NATPARA provides
Signostics has received clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company's new hand-held bladder scanner. The product is already sold in Australia and New Zealand with applications across a number of medical sectors including aged care, home nursing, midwifery, urology and palliative care.
Novartis announced today that the US Food and Drug Administration has granted accelerated approval of Bexsero for active immunization to prevent invasive meningococcal disease caused by serogroup B in adolescents and young adults from 10 years through 25 years of age. As part of the accelerated approval process, Novartis will complete its ongoing..
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Jakavi for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. "This positive CHMP opinion is encouraging news for patients with polycythemia vera who need effective treatment opti
TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced that the European Patent Office has issued European Patent EP2292736 relating to an adipose-derived stem...
GSK today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for eltrombopag, seeking an additional indication in paediatric patients six years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Array BioPharma Inc. reached an agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib, a BRAF inhibitor presently in Phase 3 development. This agreement is conditional on the closing of deals announced by GlaxoSmithKline PLC and Novartis on April 22, 2014, which are anticipated to close in the initial half of 2015, and agreem
The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Bexsero is the second vaccine approved by the FDA in the past three months to prevent this disease. With today s approval of Bexsero, the U.S. now h
The U.S. Food and Drug Administration today approved Natpara to control hypocalcemia in patients with hypoparathyroidism, a rare disease that affects approximately 60,000 people in the United States. The FDA granted Natpara orphan drug designation because it is intended to treat a rare disease. People with hypoparathyroidism have limited treatment.
The U.S. Food and Drug Administration today allowed marketing of the first set of mobile medical apps that allow people with diabetes to automatically and securely share data from a continuous glucose monitor with other people in real-time using an Apple mobile device such as an iPhone. This innovative technology has been eagerly awaited by the dia
Medtronic, Inc. today announced it has received United States Food and Drug Administration approval, under a humanitarian device exemption*, for the Medtronic Enterra II System. The system is used to treat chronic, intractable nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conservative treatments fail o
WASHINGTON, Jan. 23, 2015/ PRNewswire-USNewswire/ A tool designed to assess what interferes with acute heart failure patients' ability to care for themselves after hospital discharge holds promise for improving patient outcomes and reducing readmissions to the hospital. The patient survey, designed by researchers at Vanderbilt University, was pub